What is HC Wainwright’s Estimate for LXRX FY2024 Earnings?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities researchers at HC Wainwright lowered their FY2024 EPS estimates for shares of Lexicon Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will earn ($0.76) per share for the year, down from their prior estimate of ($0.73). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q4 2024 earnings at ($0.15) EPS, FY2025 earnings at ($0.60) EPS and FY2026 earnings at ($0.47) EPS.

A number of other analysts also recently issued reports on LXRX. Leerink Partners set a $6.00 price target on shares of Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

Lexicon Pharmaceuticals Stock Down 8.0 %

Shares of LXRX opened at $0.98 on Friday. Lexicon Pharmaceuticals has a 52 week low of $0.97 and a 52 week high of $3.73. The company has a market capitalization of $240.13 million, a price-to-earnings ratio of -1.30 and a beta of 1.24. The stock’s 50-day moving average price is $1.61 and its 200-day moving average price is $1.73. The company has a quick ratio of 11.49, a current ratio of 11.51 and a debt-to-equity ratio of 0.41.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The business had revenue of $1.75 million during the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 103.65% and a negative net margin of 4,109.41%. During the same quarter last year, the company posted ($0.21) EPS.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in LXRX. BNP Paribas Financial Markets raised its stake in shares of Lexicon Pharmaceuticals by 82.6% in the 1st quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 26,859 shares during the period. Vanguard Group Inc. raised its stake in Lexicon Pharmaceuticals by 7.0% during the 1st quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock worth $15,363,000 after acquiring an additional 420,854 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at about $3,871,000. Point72 Asset Management L.P. boosted its holdings in shares of Lexicon Pharmaceuticals by 605.2% in the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock valued at $6,924,000 after acquiring an additional 3,536,805 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Lexicon Pharmaceuticals during the first quarter worth about $105,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.